The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Babkina O.V.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

Poluéktov M.G.

Kurs somnologii pri kafedre nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Heterogeneity of excessive daytime sleepiness in Parkinson’s disease

Authors:

Babkina O.V., Poluéktov M.G., Levin O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6‑2): 60‑70

DOI: 10.17116/jnevro20161166260-70

Read: 4311 times

Contact the author
Table of contents

HETEROGENEITY OF EXCESSIVE DAYTIME SLEEPINESS IN PARKINSON’S DISEASE
HETEROGENEITY OF EXCESSIVE DAYTIME SLEEPINESS IN PARKINSON’S DISEASE

To cite this article:

Babkina OV, Poluéktov MG, Levin OS. Heterogeneity of excessive daytime sleepiness in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6‑2):60‑70. (In Russ.)
https://doi.org/10.17116/jnevro20161166260-70

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Musculoskeletal diso­rders in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):6-10
Sele­ction of patients with Parkinson’s disease for inte­rventional therapies: A review of available tools — scales and questionnaires. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):11-17
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Psycho-emotional state and self-reported sleep quality in students with bimo­dality of the ability to be active in the morning and evening in the sleep—wake cycle. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):130-134
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Change of speech diso­rders during bila­teral deep stimulation of the subthalamic nucleus of the brain in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):59-65
Analysis of the upper respiratory tracts of pate­nts with idiopathic condyle reso­rption. Russian Journal of Stomatology. 2025;(3):34-40
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Current aspe­cts of the rela­tionship between depression and cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):66-74
Abstract:

For the recent years, a special attention is given to the non-motor symptoms of Parkinson’s disease, including sleep/wake disorders representing one of the leading symptoms. Daytime sleepiness occurs in 30-55% of patients depending on duration and stage of the disease, leading to severe maladjustment. This symptom seems to be multifactorial by nature and identification of it’s causes could have a great importance for the therapy. The main factors of the development of daytime sleepiness in Parkinson’s disease and key points of the pathogenesis of «primary» daytime sleepiness are discussed. Diagnostic methods and treatment opportunities are considered as well.

Keywords:

excessive daytime sleepiness
hypersomnolence
«sleep attacks»
Parkinson’s disease
orexin

Authors:

Babkina O.V.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

Poluéktov M.G.

Kurs somnologii pri kafedre nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Close metadata

References:

  1. Parkinson J. An essay on the shaking palsy. J Neuropsychiatry ClinNeurosci. 2002;14(2):223-236.
  2. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson’s disease. A self-reported, community-based survey. Sleep Med. 2002;3(2):147-149.
  3. Porter B, Macfarlane R, Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson’s disease. Eur J Neurol. 2008;5(1):50-54.
  4. Barone P, Antonini A, Colosimo C et al. PRIAMO study group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641-1649. doi: 10.1002/mds.22643
  5. Bjørnarå KA, Dietrichs E, Toft M. Clinical features associated with sleep disturbances in Parkinson’s disease. Clin Neurol Neurosurg. 2014;124:37-43. doi: 10.1016/j.clineuro.2014.06.027
  6. Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F. A nationwide survey of excessive daytime sleepiness in Parkinson’s disease in France. Mov Disord. 2007;22(11):1567-1572.
  7. Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR. Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol. 2010;17(12):1428-1436. doi: 10.1111/j.1468-1331.2010.03063.x
  8. Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord. 2008;23(1):35-41.
  9. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson’s disease: is it the drugs or the disease? Neurology. 2006;67(5):853-858.
  10. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson’s disease: a controlled study. Mov Disord. 2003;18(6):668-672.
  11. Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA. Excessive daytime sleepiness and it’s risk factorsin incident Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84:233-234. doi: 10.1136/jnnp-2012-304097
  12. Ryan M, Slevin JT, Wells A. Non-ergot dopamine agonist-induced sleep attacks. Pharmacotherapy. 2000;20(6):724-726.
  13. Lachenmayer L. Parkinson’s disease and the ability to drive. J Neurol. 2000;247(suppl 4):IV:28-30.
  14. Schäfer D, Greulich W. Effects of parkinsonian medication on sleep. J Neurol. 2000;247(suppl 4):IV:24-27.
  15. Moller H. Antiparkinsonian drugs and «sleep attacks». CMAJ. 2001;164(7):1038-1039.
  16. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908-1910.
  17. Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75:92-97.
  18. Winkelman JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67:1034-1039.
  19. Micallef J, Rey M, Eusebio A, Audebert C, Rouby F, Jouve E et al. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol. 2009;67:333-240. doi: 10.1111/j.1365-2125.2008.03310.x
  20. Bassi S, Albizzati MG, Frattola L, Passerini D, Trabucchi M. Dopamine receptors and sleep induction in man. J Neurol Neurosurg Psychiatry. 1997;42:458-460.
  21. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson's disease. Neurology. 2007;68:1108-1115.
  22. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513-520.
  23. Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev. 2005;11(3):253-272.
  24. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931-1938.
  25. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
  26. Avorn J, Schneeweiss S, Sudarsky LR, Benner J, Kiyota Y, Levin R et al. Sudden uncontrollable somnolence and medication use in Parkinson’s disease. Arch Neurol. 2005;62:1242-1248.
  27. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18:659-667.
  28. Poryazova R, Benninger D, Waldvogel D, Bassetti CL. Excessive daytime sleepiness in Parkinson’s disease: characteristics and determinants. Eur Neurol. 2010;63(3):129-135. doi: 10.1159/000276402
  29. Möller JC, Unger M, Stiasny-Kolster K, Kaussner Y, Penzel T, Oertel WH, Hemmeter U. Continuous sleep EEG monitoring in PD patients with and without sleep attacks. Parkinsonism Relat Disord. 2009;15(3):238-241. doi:10.1016/j.parkreldis.2008.05.009
  30. Nodel' M.R., Yakhno N.N., Ukraintseva Yu.V. Gipersomniya pri bolezni Parkinsona. Nevrologicheskii zhurnal. 2014;6:9-16.
  31. Monti JM, Hawkins M, Jantos H, D’Angelo L, Fernandez M. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology (Berl). 1988;95:395-400.
  32. Levin O.S., Smolentseva I.G., Tserensodnom B. Effektivnost' pramipeksola pri bolezni Parkinsona (po dannym otkrytogo 12-mesyachnogo issledovaniya). Farmateka. 2007;11:1-8.
  33. Rye D, Bliwise D. Movement disorders specific to sleep and the nocturnal manifestations of waking movement disorders. In Watts R. and Koller W. (Eds): Movement Disorders: Neurologic Principles and Practice. McGraw-Hill, New York. 1997;687-713.
  34. Wauquier A, Clincke G, Van Den Broek W, De Prins E. Active and permissive roles of dopamine in sleep-wakefulness regulation. In Wauquier A, Gaillard JM, Monti JM and Radulovacki M. (Eds) Sleep: Neurotransmitters and Neuromodulators. Raven Press, New York. 1985;107-120.
  35. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson’s disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol. 2004;61(1):97-102.
  36. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord. 1998;13:895-899.
  37. Larsen JP. Sleep disorders in Parkinson’s disease. Adv Neurol. 2003;91:329-334.
  38. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol. 1988;11:512-519.
  39. Levin O.S., Fedorova N.V. Bolezn' Parkinsona. M.: Medpress-inform; 2014.
  40. Adler CH. Nonmotor complications in Parkinson’s disease. Mov Disord. 2005;20(suppl 11):23-29.
  41. Adler CH, Thorpy MJ. Sleep issues in Parkinson’s disease. Neurology. 2005;64:12-20.
  42. Rye DB, Bliwise DL, Dihenia B, Gurecki P. FAST TRACK: daytime sleepiness in Parkinson’s disease. J Sleep Res. 2000;9(1):63-69.
  43. Bordet R, Devos D, Brique S et al. Study of circadian melatonine secretion pattern at different stages of Parkinson’s disease. Clin Neuropharmacol. 2003;26(2):65-72.
  44. Nodel' M.R. Narusheniya sna i bodrstvovaniya pri bolezni Parkinsona: kompleksnyi podkhod k terapii. Nevrol neiropsikhiatr psikhosom. 2012;1:43-48.
  45. Bolitho SJ, Naismith SL, Rajaratnam SM, Grunstein RR, Hodges JR, Terpening Z et al. Disturbances in melatonin secretion and circadian sleep-wake regulation in Parkinson’s disease. Sleep Med. 2014;15(3):342-347. doi: 10.1016/j.sleep.2013.10.016
  46. Chang AM, Reid KJ, Gourineni R, Zee PC. Sleep Timing and Circadian Phase in Delayed Sleep Phase Syndrome. Journal of biological rhythms. 2009;24(4):313-321. doi: 10.1177/0748730409339611
  47. Kutscher SJ, Farshidpanah S, Claassen DO. Sleep dysfunction and its management in Parkinson’s disease. Curr Treat Options Neurol. 2014;16(8):304. doi: 10.1007/s11940-014-0304-7
  48. Wagner DR. Circadian Rhythm Sleep Disorders. Curr Treat Options Neurol. 1999;1(4):299-308.
  49. Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology. 2002;58:1019-1024.
  50. Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 1. Sleep disorders commonly found in older people. Cmaj. 2007;176:1299-1304. doi: 10.1503/cmaj.060792
  51. Trotti LM, Bliwise DL. No increased risk of obstructive sleep apnea in Parkinson’s disease. Mov Disord. 2010;25(13):2246-2249. doi: 10.1002/mds.23231
  52. Prudon B, Duncan GW, Khoo TK et al. Primary sleep disorder prevalence in patients with newly diagnosed Parkinson’s disease. Mov Disord. 2014;29:259-262.
  53. Alatriste-Booth V, Rodríguez-Violante M, Camacho-Ordoñez A, Cervantes-Arriaga A. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study. Arq Neuropsiquiatr. 2015;73(3):241-245. doi: 10.1590/0004-282X20140228
  54. Yong MH, Fook-Chong S, Pavanni R et al. Case control polysomnographic studies of sleep disorders in Parkinson’s disease. PLoS One. 2011;6(7):22511. doi: 10.1371/journal.pone.0022511
  55. Zeng J, Wei M, Li T, Chen W, Feng Y, Shi R, Song Y, Zheng W, Ma W. Risk of obstructive sleep apnea in Parkinson’s disease: a meta-analysis. PLoS One. 2013;8(12):82091. doi: 10.1371/journal.pone.0082091
  56. Diederich NJ, Vaillant M, Leischen M, Mancuso G, Golinval S, Nati R, Schlesser M. Sleep apnea syndrome in Parkinson’s disease. A case-control study in 49 patients. Mov Disord. 2005;20(11):1413-1418.
  57. Vincken WG, Gauthier SG, Dollfuss RE et al. Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation. N Engl JMed. 1984;311:438-442.
  58. Duncan GW, Khoo TK, Yarnall AJ, O’Brien JT, Coleman SY, Brooks DJ et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29(2):195-202. doi: 10.1002/mds.25664
  59. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol. 2014;27(4):434-441. doi: 10.1097/WCO.0000000000000112
  60. Iranzo A. Sleep-wake changes in the premotor stage of Parkinson’s disease. J Neurol Sci. 2011;310(1-2):283-285. doi: 10.1016/j.jns.2011.07.049
  61. Gao J, Huang X, Park Y, Hollenbeck A, Blair A, Schatzkin A, Chen H. Daytime napping, nighttime sleeping, and Parkinson’s disease. Am J Epidemiol. 2011;173(9):1032-1038. doi: 10.1093/aje/kwq478
  62. Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR. Pre-motor features of Parkinson’s disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord. 2012;18(suppl 1):199-202. doi: 10.1016/S1353-8020(11)70062-1
  63. Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD. Development of excessive daytime sleepiness in early Parkinson’s disease. Neurology. 2015;85(2):162-168. doi: 10.1212/WNL.0000000000001737
  64. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson’s disease: is it the drugs or the disease? Neurology. 2006;67(5):853-858.
  65. Giganti F, Ramat S, Zilli I, Guidi S, Raglione L, Sorbi S et al. Daytime course of sleepiness in de novo Parkinson’s diseae patients. J Sleep Res. 2013;22:197-200. doi: 10.1111/jsr.12000
  66. Biglan KM, Holloway RG Jr, McDermott MP, Richard IH/ Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson’s disease. Neurology. 2007;69(2):187-195.
  67. Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F. A nationwide survey of excessive daytime sleepiness in Parkinson’s disease in France. Mov Disord. 2007;22(11):1567-1572.
  68. Kato S, Watanabe H, Senda J, Hirayama M, Ito M, Atsuta N, Kaga T, Katsuno M, Naganawa S, Sobue G. Widespread cortical and subcortical brain atrophy in Parkinson’s disease with excessive daytime sleepiness. J Neurol. 2012;259(2):318-326. doi: 10.1007/s00415-011-6187-6
  69. Gjerstad MD, Aarsland D, Larsen JP. Development of daytime somnolence over time in Parkinson’s disease. Neurology. 2002;58(10):1544-1546.
  70. Jaussent I, Bouyer J, Ancelin ML, Berr C, Foubert-Samier A, Ritchie K, Ohayon MM, Besset A, Dauvilliers Y. Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep. 2012;35(9):1201-1207. doi: 10.5665/sleep.2070
  71. Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RA, Del Tredici K. Pathology associated with sporadic Parkinson’s disease - where does it end? J Neural Transm Suppl. 2006;(70):89-97.
  72. Somnologiya i meditsina sna. Natsional'noe rukovodstvo pamyati A.M. Veina i Ya.I. Levina. Pod red. Poluektova M.G. M.: Medforum; 2016.
  73. Overeem S, van Hilten JJ, Ripley BS et al. Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness. Neurology. 2002;58:494-498.
  74. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti CL. Parkinsonism with excessive daytime sleepiness - a narcolepsy-like disorder? J Neurol. 2005;252(2):139-145.
  75. Compta Y, Santamaria J, Ratti L, Tolosa E, Iranzo A, Munoz E et al. Cerebrospinal hypocretin, daytime sleepiness, and sleep architecture in Parkinson’s disease dementia. Brain. 2009;132:3308-3317.
  76. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol. 2003;184:1010-1016.
  77. Fronczek R, Overeem S, Lee SYY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Parkinson’s disease. Brain. 2007;130:1577-1585.
  78. Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Créange A, Remy P, Goldenberg F, d’Ortho MP. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology. 2003;61(4):540-543.
  79. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain. 2007;130(6):1586-1595.
  80. Torterolo P, Sampogna S, Morales FR, Chase MH. MCH-containing neurons in the hypothalamus of the cat: searching for a role in the control of sleep and wakefulness. Brain Res. 2006;1119:101-114.
  81. Videnovic A, Golombek D. Circadian and Sleep Disorders in Parkinson’s Disease. Experimental neurology. 2013;243:45-56. doi: 10.1016/j.expneurol.2012.08.018
  82. Murillo-Rodriguez E, Arias-Carrion O, Sanguino-Rodriguez K, Gonzalez-Arias M, Haro R. Mechanisms of sleep-wake cycle modulation. CNSNeurol Disord Drug Targets. 2009;8:245-253.
  83. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev. 2007;11:113-133.
  84. Monaca C, Laloux C, Jacquesson JM, Gele P, Marechal X, Bordet R, Destee A, Derambure P. Vigilance states in a parkinsonian model, the MPTP mouse. Eur J Neurosci. 2004;20:2474-2478.
  85. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E. Tison F, Ghorayeb I. Sleep disorders in Parkinson’s disease: the contribution of the MPTP non-human primate model. Exp Neurol. 2009;219:574-582.
  86. Decker MJ. Keating G, Hue GE, Freeman A, Rye DD. Mesolimbic dopamine’s modulation of REM sleep. J Sleep Res (supl). 2002;51:51-52.
  87. Hilker R, Razai N, Ghaemi M et al. [18F] fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson’s disease. Clin Neurol. 2003;105:262-269.
  88. Saper CB, Lu J, Chou TC et al. The hypothalamic integrator for circadian rhythms. Trend Neurosci. 2005;28:152-157.
  89. Jost WH. Autonomic dysfunctions in idiopathic Parkinson’s disease. J Neurol. 2003;250(suppl 1):218-130.
  90. Moya A, Sutton R, Ammirati F et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30(21):2631-2671. doi: 10.1093/eurheartj/ehp298
  91. Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17(10):724-729. doi: 10.1016/j.parkreldis.2011.04.016
  92. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson’s disease. Clin Auton Res. 2006;16(1):46-54.
  93. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicenter study. J NeurolNeurosurg Psychiatry. 1999;66(4):436-441.
  94. Jost WH, Bellon AK, Kaiser T, Schrank B. The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. Parkinsonism Relat Disord. 1998;4(2):61-63.
  95. Freeman R, Wieling W, Axelrod FB et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161(1-2):46-48. doi: 10.1016/j.autneu.2011.02.004
  96. Umehara T, Toyoda C, Oka H. Postprandial hypotension in de novo Parkinson’s disease: a comparison with orthostatic hypotension. Parkinsonism Relat Disord. 2014;20(6):573-577. doi:10.1016/j.parkreldis.2014.02.007
  97. Le Couteur DG, Fisher AA, Davis MW, McLean AJ. Postprandial systolic blood pressure responses of older people in residential care: association with risk of falling. Gerontology. 2003;49:260-264.
  98. Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(5):501-505. doi:10.1016/j.parkreldis.2012.01.012
  99. Maurer MS, Karmally W, Rivadeneira H, Parides MK, Bloomfield DM. Upright posture and postprandial hypotension in elderly persons. Ann Intern Med. 2000;133:533-536.
  100. Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR. Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol. 2010;17(12):1428-1436. doi: 10.1111/j.1468-1331.2010.03063.x
  101. Chung S, Bohnen NI, Albin RL, Frey KA, Müller MLTM, Chervin RD. Insomnia and Sleepiness in Parkinson’s Disease: Associations with Symptoms and Comorbidities. Journal of Clinical Sleep Medicine: JCSM : Official Publication of the American Academy of Sleep Medicine. 2013;9(11):1131-1137. doi:10.5664/jcsm.3150
  102. Beiske AG, Svensson E. Fatigue in Parkinson’s disease: a short update. Acta Neurol Scand Suppl. 2010;(190):78-81. doi: 10.1111/j.1600-0404.2010.01381.x
  103. Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson’s disease? Neurology. 2004;63(10):1908-1911.
  104. Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson’s disease. Mov Disord. 2010;25(suppl 1):117-122. doi: 10.1002/mds.22788
  105. Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Ann Neurol. 2008;64(suppl 2):65-80. doi: 10.1002/ana.21472
  106. Wee N, Kandiah N, Acharyya S, Chander RJ, Ng A, Au WL, Tan LC. Depression and anxiety are co-morbid but dissociable in mild Parkinson’s disease: A prospective longitudinal study of patterns and predictors. Parkinsonism Relat Disord. 2016;23:50-56. doi: 10.1016/j.parkreldis.2015.12.001
  107. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord. 1999;14(6):922-927.
  108. Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM. Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson’s disease and in their caregivers. Parkinsonism Relat Disord. 2004;10(3):157-168.
  109. McNamara P, Durso R, Auerbach S. Dopaminergic syndromes of sleep, mood and mentation: evidence form Parkinson’s disease and related disoerders. Sleep Hypnosis. 2002;4(4):119-131.
  110. Friedman JH, Chou KL. Sleep and fatigue in Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(suppl 1):27-35.
  111. Breslau N, Roth T, Rosenthal L, Andreski P. Daytime sleepiness: an epidemiological study of young adults. Am J Public Health. 1997;87:1649-1653.
  112. Ataide M, Franco CMR, Lins OG. Daytime Sleepiness in Parkinson’s Disease: Perception, Influence of Drugs, and Mood Disorder. Sleep Disord. 2014;3:5. doi:10.1155/2014/939713
  113. Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatry. 2006;21(3):252-258.
  114. Merino-Andreu M, Arnulf I, Konofal E, Derenne JP, Agid Y. Unawareness of naps in Parkinson’s disease and in disorders with excessive daytime sleepiness. Neurology. 2003;60(9):1553-1554.
  115. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545.
  116. Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C,Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG. Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations. Mov Disord. 2010;25(16):2704-2716. doi: 10.1002/mds.23190
  117. Carskadon MA, Dement WC. Effects of total sleep loss on sleep tendency. Percept Mot Skills. 1979;48(2):495-506.
  118. Todd J. Swick. Parkinson’s Disease and Sleep/Wake Disturbances. Parkinson’s Disease. 2012;205471:14. doi:10.1155/2012/205471
  119. Stevens S, Cormella CL, Stepanski EJ. Daytime sleepiness and alertness in patients with Parkinson’s disease. Sleep. 2004;27:967-972.
  120. Louter M, Arends JB, Bloem BR, Overeem S. Actigraphy as a diagnostic aid for REM sleep behavior disorder in Parkinson’s disease. BMC Neurol. 2014;14:76.
  121. Shtok V.N., Ivanova-Smolenskaya I.A., Levin O.S. i dr. Ekstrapiramidnye rasstroistva. M.: MEDpress-inform; 2002.
  122. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5-15. doi:10.1111/j.1468-1331.2012.03866.x
  123. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009;329(2):738-746.
  124. Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: Systematic review and meta-analysis. Parkinsonism Relat Disord. 2016. doi:10.1016/j.parkreldis.2016.03.002
  125. Postuma RB, Lang AE, Munhoz RP et al. Caffeine for treatment of Parkinson’s disease: A randomized controlled trial. Neurology. 2012;79(7):651-658. doi:10.1212/WNL.0b013e318263570d
  126. Videnovic A, Noble C, Reid KJ et al. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson’s disease. JAMA neurology. 2014;71(4):463-469. doi:10.1001/jamaneurol.2013.6239
  127. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA et al. Effect of exogenous melatonin on sleep and motor dysfunction in PD. A randomized, double blind, placebo controlled study. J Neurol. 2007;254(4):459-469.
  128. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005;6:459-466.
  129. Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A. The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson’s Disease. Mov Disord. 2016;31(1):23-38. doi: 10.1002/mds.26484
  130. Nascimento CM, Ayan C, Cancela JM, Gobbi LT, Gobbi S, Stella F. Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson’s and Alzheimer’s disease patients. Geriatr Gerontol Int. 2014;14(2):259-266.
  131. Golden RN, Gaynes BN, Ekstrom RD et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. American Journal of Psychiatry. 2005;162(4):656-662.
  132. Mishima K, Okawa M, Hishikawa Y, Hozumi S, Hori H, Takahashi K. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatrica Scandinavica. 1994;89(1):1-7.
  133. Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson’s disease: a pilot study. Movement Disorders. 2007;22(10):1495-1498.
  134. Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Reviews in the Neurosciences. 2012;23(2):199-226.
  135. Levin Ya.I., Artemenko A.R. Fototerapiya. M.: TriL; 1996.
  136. Hjort N, Ostergaard K, Dupont E. Improvement of sleep quality in patients with advanced Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord. 2004;19:196-199.
  137. Cicolin A, Lopiano L, Zibetti M, Torre E, Tavella A, Guastamacchia G et al. Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med. 2004;5(2):207-210.
  138. Chahine LM, Ahmed A, Sun Z. Effects of STN DBS for Parkinson’s disease on restless legs syndrome and other sleep-related measures. Parkinsonism Relat Disord. 2011;17(3):208-211. doi: 10.1016/j.parkreldis.2010.11.017
  139. Peppe A, Pierantozzi M, Baiamonte V et al. Deep Brain Stimulation of Pedunculopontine Tegmental Nucleus: Role in Sleep Modulation in Advanced Parkinson’s Disease Patients - One-Year Follow-Up. Sleep. 2012;35(12):1637-1642. doi:10.5665/sleep.2234
  140. Arnulf I, Ferraye M, Fraix V, Benabid AL, Chabardès S, Goetz L, Pollak P, Debû B. Sleep induced by stimulation in the human pedunculopontine nucleus area. Ann Neurol. 2010;67(4):546-549. doi: 10.1002/ana.21912
  141. Griebel G, Decobert M, Jacquet A, Beeské S. Awakening properties of newly discovered highly selective H₃ receptor antagonists in rats. Behav Brain Res. 2012;232(2):416-420. doi: 10.1016/j.bbr.2012.04.033
  142. Ondo WG, Perkins T, Swick T et al. Sodium oxybate for excessive daytime sleepiness in Parkinson’s disease: an open-label polysomnographic study. Arch Neurol. 2008;65:1337-1340.
  143. Szabo ST, Gold MS, Goldberger BA, Blier P. Effects of sustained gammahydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biol Psychiatry. 2004;55(9):934-939.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.